VA Consolidation in Intermediate-Risk AML
Recruiting
Phase 2
Interventional Study
Acute Myeloid Leukemia
Intermediate Risk Acute Myeloid Leukemia
Consolidation Therapy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 226 (estimated)
- Sponsor
- The First Affiliated Hospital of Soochow University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This clinical trial aims to compare the efficacy and safety of venetoclax-based consolidation therapy versus conventional consolidation chemotherapy (intermediate/high-dose cytarabine) in newly diagnosed adult patients with intermediate-risk acute myeloid leukemia (AML). Participants must have achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi) after induction therapy…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Confirmed diagnosis of acute myeloid leukemia (AML) according to WHO 2022 classification criteria;
* Age ≥ 18 years;
* Classified as intermediate-risk based on European LeukemiaNet (ELN) 2022 prognostic risk stratification;
* Achieved first complete remission (CR) or CR with i…
Contacts